Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Current Ratio: 2.31 (As of Dec. 2025) — 32% Above Median


FRA:I54 Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
82 GF Score
Price €5.00
GF Value €3.63
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Biocytogen Pharmaceuticals (Beijing) Co Current Ratio?

Biocytogen Pharmaceuticals (Beijing) Co FRA:I54 -2.91% 82 Current Ratio is 2.31 as of Dec. 2025, which is 32% above its 10-year median of 1.75. GuruFocus rates FRA:I54 with a GF Score™ of 82/100 and a GF Value™ of €3.63 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Biocytogen Pharmaceuticals (Beijing) Co ranks worse than 64.49% on this metric.

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Biocytogen Pharmaceuticals (Beijing) Co's current ratio for the quarter that ended in Dec. 2025 was 2.31.

Biocytogen Pharmaceuticals (Beijing) Co has a current ratio of 2.31. It generally indicates good short-term financial strength.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's Current Ratio or its related term are showing as below:

FRA:I54' s Current Ratio Range Over the Past 10 Years
Min: 1.25   Med: 1.75   Max: 3.49
Current: 2.31

During the past 6 years, Biocytogen Pharmaceuticals (Beijing) Co's highest Current Ratio was 3.49. The lowest was 1.25. And the median was 1.75.

FRA:I54's Current Ratio is ranked worse than
64.49% of 1411 companies
in the Biotechnology industry
Industry Median: 3.91 vs FRA:I54: 2.31

Biocytogen Pharmaceuticals (Beijing) Co  (FRA:I54) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Biocytogen Pharmaceuticals (Beijing) Co Current Ratio Related Terms


Biocytogen Pharmaceuticals (Beijing) Co Current Ratio Historical Data

* Premium members only.

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co Current Ratio Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Ratio
Get a 7-Day Free Trial 1.96 1.52 1.25 1.53 2.31

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.25 1.34 1.53 1.89 2.31

FRA:I54 vs VRTX, REGN, ALNY: Current Ratio Comparison

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co Current Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Current Ratio distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Current Ratio falls into.


FRA:I54
82GF Score
Biocytogen Pharmaceuticals (Beijing) Co Ltd FRA:I54
Current Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biocytogen Pharmaceuticals (Beijing) Co Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Biocytogen Pharmaceuticals (Beijing) Co's Current Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Current Ratio (A: Dec. 2025 )=Total Current Assets (A: Dec. 2025 )/Total Current Liabilities (A: Dec. 2025 )
=260.542/112.801
=2.31

Biocytogen Pharmaceuticals (Beijing) Co's Current Ratio for the quarter that ended in Dec. 2025 is calculated as

Current Ratio (Q: Dec. 2025 )=Total Current Assets (Q: Dec. 2025 )/Total Current Liabilities (Q: Dec. 2025 )
=260.542/112.801
=2.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Current Ratio →
What does a Current Ratio of 2.31 mean?
Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) has a Current Ratio of 2.31 as of Dec. 2025. This is 32% above median its historical median of 1.75. Over the past decade, Biocytogen Pharmaceuticals (Beijing) Co's Current Ratio has ranged from 1.25 to 3.49. According to the industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #910 out of 1411 companies in the Biotechnology industry, placing it in the top 64.5%.
Is Biocytogen Pharmaceuticals (Beijing) Co's Current Ratio too high?
Biocytogen Pharmaceuticals (Beijing) Co's current Current Ratio of 2.31 is 32% above median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 1.25 to a high of 3.49. The Biotechnology industry median Current Ratio is 3.91. Biocytogen Pharmaceuticals (Beijing) Co's value of 2.31 is 40.9% below this industry median. Based on the distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #910 out of 1411 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Biocytogen Pharmaceuticals (Beijing) Co has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biocytogen Pharmaceuticals (Beijing) Co's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biocytogen Pharmaceuticals (Beijing) Co ranks #910 out of 1411 companies for Current Ratio. This places Biocytogen Pharmaceuticals (Beijing) Co in the lower half of its industry. The industry median Current Ratio is 3.91. Biocytogen Pharmaceuticals (Beijing) Co's value of 2.31 is 40.9% below this benchmark. Historically, Biocytogen Pharmaceuticals (Beijing) Co's own Current Ratio has ranged from 1.25 to 3.49 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 3.91, Biocytogen Pharmaceuticals (Beijing) Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biocytogen Pharmaceuticals (Beijing) Co's current Current Ratio of 2.31 is 40.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biocytogen Pharmaceuticals (Beijing) Co's current Current Ratio is 2.31, which is 32% above median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biocytogen Pharmaceuticals (Beijing) Co stock overvalued right now?
Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.63, compared to a current price of €5.00 — trading 37.7% above its estimated fair value. The current Current Ratio is 2.31, which is 32% above median its 10-year median of 1.75 and 40.9% below the Biotechnology industry median of 3.91. Biocytogen Pharmaceuticals (Beijing) Co's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54), the current Current Ratio is 2.31 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Overvalued in 2026?

Based on GuruFocus' analysis, Biocytogen Pharmaceuticals (Beijing) Co stock appears to be overvalued. The current stock price of €5.00 is trading 37.7% above its estimated GF Value™ of €3.63. GuruFocus considers Biocytogen Pharmaceuticals (Beijing) Co to be Significantly Overvalued.

Key valuation signals for FRA:I54:

  • Current Ratio: 2.31 (32% above median its 10-year median of 1.75)
  • GF Value™: €3.63 vs. price of €5.00 (37.7% above fair value)
  • GF Score™: 82/100 with 2 warning signs
  • Industry Position: 40.9% below the Biotechnology median (#910 of 1411)

No single metric tells the full story. See the FRA:I54 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biocytogen Pharmaceuticals (Beijing) Co Business Description

Other Exchanges 02315:Hong Kong688796:China
Address 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
82GF Score

Get the complete analysis for FRA:I54

Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.00
Price
€3.63
GF Value